

## Special Issue

# Biomarkers and Lung Cancer: Clinical Application

### Message from the Guest Editor

Lung cancer is the leading cause of cancer-related mortality worldwide. The five-year survival rate is strongly associated with late diagnosis (23% for stage III–IV vs. 67% for the early stages). Screening programs based on low-dose computed tomography (LD-CT) determined a 20% reduction in lung cancer mortality. However, it is not very suitable as a screening test for the mass population due to its high costs, radiation, and false positive rate. Thus, early diagnosis is essential for its therapeutic and prognostic implications. The discovery of lung cancer biomarkers in body fluids such as blood, urine, stool, saliva, sputum and breath could play a key role in the diagnosis, prognosis and treatment of lung cancer. The goal of this Special Issue is to share new knowledge about the latest biomolecules and techniques available for minimally invasive screening of lung cancer as well as the critical limitations that require future improvement in order to upgrade the diagnosis, prognosis and treatment of lung cancer patients. We hope this Special Issue will be of interest to you, and we look forward to receiving your contributions.

### Guest Editor

Dr. Roberto Gasparri

Department of Thoracic Surgery, European Institute of Oncology, Via Giuseppe Ripamonti 435, 20141 Milan, Italy

### Deadline for manuscript submissions

30 October 2025



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/193026](https://mdpi.com/si/193026)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).